In 2005, research published at the annual American Society of Reproductive Medicine conference sparked controversy.  This research, published by Marinko Biljan M.D., found that the use of Femara (letrozole) during pregnancy was associated with an increased risk for birth defects.  Biljan found that among 150 pregnancies in women who used Femara, 4.7% of children were